GeoVax Labs, Inc.

ATLANTA, GA -- (Marketwired) -- 05/02/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2013 and provided a clinical development update. "GeoVax continues to make steady progress in our quest to develop effective preventive and ... read more

ATLANTA, GA -- (Marketwire) -- 03/11/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2012 and provided a business update. "GeoVax continues its successful, steady progress with the clinical development of HIV/AIDS ... read more

ATLANTA, GA -- (Marketwire) -- 01/23/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, unveiled its new website January 23rd. The site, www.geovax.com, incorporates numerous features to make browsing a more fruitful experience for the Company's current and potential investors. The ... read more

ATLANTA, GA -- (Marketwire) -- 01/15/13 -- Robert T. McNally, Ph.D., President & CEO of GeoVax Labs (OTCQB: GOVX), along with David A. Dodd, Chairman of the Board, today issued the following update letter to shareholders: Dear Fellow Shareholders, Since our last shareholder update letter in May 2012, we have continued ... read more

ATLANTA, GA -- (Marketwire) -- 01/10/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune ... read more

ATLANTA, GA -- (Marketwire) -- 12/13/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, was featured in five publications during the past two weeks, a period also marked by the observance of World AIDS Day ... read more

ATLANTA, GA -- (Marketwire) -- 11/29/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced that Robert T. McNally, Ph.D., President and CEO, will present at the fifth annual LD Micro Conference on Wednesday, December 5, ... read more

ATLANTA, GA -- (Marketwire) -- 11/14/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the nine months ended September 30, 2012 and provided a business update. GeoVax's President and CEO Robert McNally, Ph.D., commented, "The third quarter ... read more

ATLANTA, GA -- (Marketwire) -- 10/05/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced that Robert T. McNally, Ph.D., President and CEO, will present at the 11th Annual BIO Investor Forum on Wednesday, October ... read more

ATLANTA, GA -- (Marketwire) -- 10/01/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced receipt of a $1.9 million award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes ... read more

ATLANTA, GA -- (Marketwire) -- 09/26/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, was featured in several presentations at the AIDS Vaccine 2012 Conference in Boston, September 10-12. The HIV Vaccine Trials Network (HVTN), which is funded by the National ... read more

ATLANTA, GA -- (Marketwire) -- 09/04/12 -- GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City. Robert McNally, Ph.D., President and CEO of ... read more

ATLANTA, GA -- (Marketwire) -- 08/13/12 -- GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, announced its financial results for the six months ended June 30, 2012 and provided a business update. David Dodd, GeoVax's Chairman of the Board, remarked, "During ... read more

ATLANTA, GA -- (Marketwire) -- 07/12/12 -- GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), an Atlanta-based biotechnology firm developing vaccines to prevent and treat Human Immunodeficiency Virus (HIV) infections, is presenting at the SeeThruEquity MicroCap Investor Forum taking place July 18 in New York City at The Cornell Club, ... read more

ATLANTA, GA -- (Marketwire) -- 06/11/12 -- GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), an Atlanta-based biotechnology firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, is attending the BIO International Convention taking place June 18-21 in Boston, MA at the Boston Convention & Exhibition Center, ... read more